Engineering Cures

From Within

Program any immune cell.
Scale globally.

About us

CREATE Medicines is pioneering multi-immune programming with its versatile in vivo CAR platform. Our proprietary mRNA-LNP CARs and targeted receptor/LNP technologies enable direct programming of T cells, NK cells, and myeloid cells within the body. CREATE's in vivo CAR products have demonstrated first-in-human evidence of uptake, expression, and tolerable repeat dosing.

What sets CREATE apart:

Proprietary receptor and RNA engineering, including retrotransposon-mediated stability options
First-in-human clinical data confirming mechanism of action
Multilineage programming across immune cell types (T, NK, myeloid)
Demonstrated tolerability with repeat dosing

Our team

We believe breakthroughs come from creators, not convention. Our cross-disciplinary team with expertise in selective receptor design, RNA engineering, targeted LNP delivery, and immunology is forging a new approach to immunotherapy, unlocking scalable, off-the-shelf therapies with unmatched speed, lower costs, and broader patient access across cancer, autoimmunity, and fibrosis.

Daniel Getts, PhD

Chief Executive Officer, Cofounder, Board Director

Allan Shaw

Chief Business Officer and Chief Financial Officer

Robert Hofmeister, PhD

Chief Scientific Officer

Matthew Maurer, MD

Chief Medical Officer

Curtis Demick

Chief People Officer

Jason Walsh

Chief Financial Operations Officer

Michele Cioffi

Senior Vice President, Clinical

Yuxiao Wang, PhD

Cofounder, Vice President, Discovery Research

Heather Cohen, PhD

Vice President, Precision Medicine and Biomarkers

Jerome Chal, PhD

Senior Vice President, Head of CMC

Jian Ding, PhD

Vice President, Translational Research

Our pipeline

CREATE’s multi-immune in vivo CAR platform has generated assets that overcome barriers in solid tumors.

Clinical data confirms:

Tolerable safety and repeat IV dosing
Antigen presentation
Multi-immune mRNA uptake and CAR expression
Cytokine and chemokine release
Immune cell tumor infiltration
Induction of antitumor immune response in TME

Building on this foundation, CREATE is advancing multi-cell targeting in solid tumors and expanding into hematologic malignancies and autoimmune diseases to unlock the full potential of our platform for patients.

Product

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Multi-immune Cell ProgrammingT, NK, and myeloid cells

MT-304

Breast cancer

Phase 1

CRT-401

Epithelial tumors

Preclinical

CRT-402

B cell depletion

Preclinical

Myeloid Cell Programming

MT-303

Frontline HCC

Phase 2

MT-302

Frontline GEJ (IST)

Phase 2

Join us

Bold science. Bold culture. Our modular, in vivo immune programming platform may be highly structured, but our culture thrives on flexibility and creativity. It is dynamic, driven, and built for those who want to create at the edge of what is possible. We move fast, think big, and work as one, pioneering a new class of therapeutics, together.

Creating from within:The builders behind the breakthrough

Creating the impossible. We are problem-solvers and medicine-makers on a mission to deliver programmable, powerful treatments for diseases once thought untreatable. Join the immune programming revolution.

Explore Open Positions